pSivida announces China licensee

Oct. 28, 2005 — pSivida Ltd. (NASDAQ:PSDV) announced it signed a license with Beijing Med-Pharm Corp. for the clinical development, marketing and distribution of pSivida’s lead product, BrachySil, in China.

Under the terms of the license, pSivida will manufacture BrachySil and Beijing Med-Pharm will be responsible for clinical development, securing regulatory approval, marketing and distribution in China. pSivida will retain manufacturing rights for BrachySil. A manufacturing and supply agreement for pSivida to supply BrachySil to Beijing Med-Pharm is slated to be done within 90 days.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.